Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.63
- Piotroski Score 2.00
- Grade Outperform
- Symbol (APTO)
- Company Aptose Biosciences Inc.
- Price $0.24
- Changes Percentage (-12.36%)
- Change -$0.03
- Day Low $0.23
- Day High $0.30
- Year High $2.91
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.09
- Trailing P/E Ratio -0.15
- Forward P/E Ratio -0.15
- P/E Growth -0.15
- Net Income $-51,207,000
Income Statement
Quarterly
Annual
Latest News of APTO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Barrett scores season-high 39 as Raptors snap 7-game losing streak, beat Pacers 130-119
The Toronto Raptors ended a seven-game losing streak with a 130-119 victory over the Indiana Pacers. RJ Barrett scored 39 points, Jakob Poeltl had 30 points and 15 rebounds, and the Raptors had all fi...
By AP NEWS | 3 days ago -
RJ Barrett's passing as Toronto Raptors' main option has been revelatory
RJ Barrett's decision-making in clutch moments shows promise for the Raptors. As the team's top playmaker, he is evolving with solid passing and leadership. Despite close losses, Barrett's growth as a...
By The New York Times | 3 days ago -
Detroit Pistons beat Toronto Raptors 99-95 to remain undefeated in NBA Cup play
Malik Beasley and Cade Cunningham led the Detroit Pistons to a 99-95 victory over the Toronto Raptors. Despite poor 3-point shooting, the Pistons prevailed. Jakob Poeltl's strong performance wasn't en...
By CBS News | 5 days ago
